NRP2 and neoplasm: Likewise, the cell-penetrating peptide iRGD containing the CendR sequence can first target integrin receptor to cross the blood–brain barrier and then provides the second moiety to bind Neuropilin-1 (NRP-1) and Neuropilin-2 (NRP-2) for crossing the brain–tumor barrier (73).